TNFSF13B and systemic lupus erythematosus: In a Swedish LN cohort, low baseline levels of serum BAFF were shown to be predictive of the clinical and histopathological responses to therapy, the latter based on per-protocol repeat biopsies, demonstrating a PPV of 92% for the clinical response in a subgroup of SLE patients with proliferative nephritis [135].